PROPRIETARY PROTEIN CRYSTALS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SGX is a structure guided drug discovery company accelerating the discovery of novel therapeutics to treat human diseases. SGX has developed FAST¿¿¿¿¿a"¿¿¿ (Fragments of Active Structures), a proprietary technology for rapid identification of novel, potent and selective small molecule inhibitors of drug targets. FAST¿¿¿¿¿a"¿¿¿ relies on libraries of synthetically enabled fragments developed by SGX, to ensure rapid hit-to-lead optimization and draws on SGX high-throughput X-ray co-crystallography, state of the art computational scoring and automated parallel synthesis. SGX technology drives the lead optimization process through iterative determination of co-crystal structures that reveal, in atomic detail, how small molecules interact with drug targets. SGX leverages FAST¿¿¿¿¿a"¿¿¿ for programs focused in oncology as well as partnered programs in other disease areas.